Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Comprehensive DNA sequencing reveals hidden drivers of cancer (opens in a new tab)

medicalxpress.com · 2026-10-22

Short answerEvidenceSource

Short answer

Mixed

Mixed.

One key claim is not backed by the study. One other point was not covered by the paper.

  • 3 supported
  • 1 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

One claim isn't supported by the study. Three of five check out. One claim the study doesn't address.

  • 3 supported
  • 1 not supported
  • 1 not covered
Open claim evidence
3
Source paper

Source layer

The 3 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not supportedIn a separate New England Journal of Medicine report, nanopore sequencing was used to trace a rare tumor in a 3-year-old boy after AAV gene therapy for Krabbe disease, and the team found a fragment of modified AAV DNA inserted into GLI1 that drove unusually high GLI1 activity.View evidenceHide evidence

As stated26 months after gene therapy

Why this verdict

The supplied paper profile is for the Cancer Discovery nanopore/oncology-phasing study and contains no evidence about a separate New England Journal of Medicine AAV gene-therapy case, Krabbe disease, a paraspinal tumor, GLI1 insertion, or GLI1 overactivity. Relative to the supplied profile, the separate causal case-report claim is unsupported.

Claim 2 of 5Not coveredThe article says long-read sequencing also uncovered an inherited cancer-risk variant missed by prior commercial testing: a disease-causing DNA insertion in BRCA2 was found in a woman with a strong family history of breast and ovarian cancer.View evidenceHide evidence

Why this verdict

The supplied abstract-level profile does not mention an inherited BRCA2 insertion, blood-sample nanopore sequencing, prior commercial testing, or the family-history case. This may be a full-text or related-report detail, but it is not verifiable from the abstract profile provided.

Claim 3 of 5SupportedMichigan's MiOncoSeq program, launched in 2010, sequences patient tumors to identify alterations that could help guide treatment, and a new study in Cancer Discovery added long-read nanopore sequencing to detect changes conventional sequencing might miss.View evidenceHide evidence

Why this verdict

The abstract-level profile supports the core claim that the Cancer Discovery study used long-read nanopore sequencing/haplotype phasing to detect or resolve alterations and allelic configurations missed or not phaseable by short-read sequencing. MiOncoSeq is represented as a clinical sequencing dataset/workflow in the profile. The specific launch year, 2010, is not verified in the abstract profile, but it is ancillary to the scientific claim.

1

Study evidence

Mutational-signature analysis on a 768-patient clinical sequencing cohort nominated 46 'cryptic' genomic-instability tumors that lacked an explanatory biallelic event on short-read data.46 nominated cases (from 768 patients)

“Among 768 patients with prostate, breast, or ovarian cancers, we used mutational signatures to nominate cryptic genomic instability cases lacking a causative biallelic event on short-read sequencing.”
2

Study evidence

In 4,496 MiOncoSeq samples the authors identified 17,519 multi-hit gene variant pairs; 78.7% of those pairs were separated by >500 bp, exceeding the short-read phasing limit.17,519 pairs; 78.7% >500 bp

“Analysis of 4,496 MiOncoSeq samples identified 17,519 multi-hit gene pairs, 78.7% of which exceeded the 500 bp short-read phasing limit”
Claim 4 of 5SupportedIn one arm of the study, the researchers screened 768 patients with prostate, breast or ovarian cancer, found 46 tumors with unexplained genomic instability, and long-read sequencing resolved 32 of those cases by identifying hidden alterations or chemical changes affecting cancer-protective genes.View evidenceHide evidence

As stated768 patients; 46 tumors; 32 cases

Why this verdict

This matches the abstract evidence: among 768 patients with prostate, breast, or ovarian cancers, mutational signatures nominated 46 cryptic genomic-instability cases, and long-read nanopore sequencing resolved 32/46 through methylation detection, long-insertion resolution, and structural-variant characterization, confirming trans inactivation in resolved tumor-suppressor cases.

1

Study evidence

Mutational-signature analysis on a 768-patient clinical sequencing cohort nominated 46 'cryptic' genomic-instability tumors that lacked an explanatory biallelic event on short-read data.46 nominated cases (from 768 patients)

“Among 768 patients with prostate, breast, or ovarian cancers, we used mutational signatures to nominate cryptic genomic instability cases lacking a causative biallelic event on short-read sequencing.”
Claim 5 of 5SupportedIn a broader analysis, the team screened 4,496 tumor samples from 3,688 patients and used nanopore sequencing in selected cases to determine how mutations were arranged in genes including NOTCH1, PDGFRB, KIT and PIK3CA.View evidenceHide evidence

As stated4,496 tumor samples from 3,688 patients

Why this verdict

The profile supports the 4,496 MiOncoSeq-sample analysis and the use of long-read phasing to reveal recurrent compound cis alleles in NOTCH1, PIK3CA, PDGFRB, and KIT. The abstract profile does not independently verify the story's added denominator of 3,688 patients, but it supports the main scientific content and the 4,496-sample figure.

1

Study evidence

In 4,496 MiOncoSeq samples the authors identified 17,519 multi-hit gene variant pairs; 78.7% of those pairs were separated by >500 bp, exceeding the short-read phasing limit.17,519 pairs; 78.7% >500 bp

“Analysis of 4,496 MiOncoSeq samples identified 17,519 multi-hit gene pairs, 78.7% of which exceeded the 500 bp short-read phasing limit”
2

Study evidence

Long-read phasing revealed recurrent compound cis alleles in NOTCH1, PIK3CA, PDGFRB, and KIT.

“long-read phasing revealed recurrent compound cis alleles in NOTCH1, PIK3CA, PDGFRB, and KIT.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Large MiOncoSeq-scale quantification: 4,496 samples contained 17,519 multi-hit gene variant pairs, 78.7% of which exceeded the approximate 500 bp short-read phasing limit.

    The story mentions the 4,496-sample analysis but does not report the 17,519 multi-hit-pair count or the 78.7% figure, which is a material quantitative motivation for long-read phasing in the abstract.

    From Retrospective cohort computational analysis

4 things the story did carry across
  • Primary abstract finding: mutational-signature nomination of 46 cryptic genomic-instability tumors from 768 prostate, breast, or ovarian cancer patients, with long-read nanopore sequencing resolving 32/46 cases through methylation, long-insertion, and structural-variant mechanisms.
  • Allelic-configuration finding: in resolved tumor-suppressor cases, long-read phasing supported trans/biallelic inactivation, addressing a gap left by short-read sequencing.
  • Recurrent compound cis oncogenic alleles were revealed in NOTCH1, PIK3CA, PDGFRB, and KIT by long-read phasing.
  • Clinical interpretation should remain forward-looking: the abstract proposes integrating haplotype phasing into precision-oncology workflows but does not establish a new routine standard of care or demonstrate treatment-outcome benefit.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoUse mutational-signature nomination to find “cryptic” genomic instability tumors that lack an explanatory biallelic event by short-read sequencing, and resolve them with long-read nanopore sequencing to determine allelic configuration and complex variant mechanisms (including methylation, long insertions, and structural variants), confirming trans tumor-suppressor inactivation when present.Observational clinical sequencing cohort with computational nomination and targeted long-read sequencingExpand

In plain English

In a cohort of 768 patients with prostate, breast, or ovarian cancers, the authors used mutational-signature analysis on short-read clinical sequencing to nominate 46 "cryptic" genomic-instability tumors that lacked an explanatory biallelic event by short-read data. Targeted long-read nanopore sequencing (with methylation calling, long-insertion resolution, structural-variant characterization, and haplotype phasing) resolved 32 of the 46 nominated cases (69.6%), and in every resolved tumor-suppressor case the long-read data supported trans (biallelic) inactivation. The study frames long-read haplotype phasing as a means to close an interpretation gap left by short-read sequencing.

Key findings

  • Mutational-signature analysis on a 768-patient clinical sequencing cohort nominated 46 'cryptic' genomic-instability tumors that lacked an explanatory biallelic event on short-read data.46 nominated cases (from 768 patients)
  • Long-read nanopore sequencing resolved 32 of 46 nominated cryptic cases, using methylation detection, long-insertion resolution, and structural-variant characterization to enable phasing.32 of 46 (69.6%)
“Among 768 patients with prostate, breast, or ovarian cancers, we used mutational signatures to nominate cryptic genomic instability cases lacking a causative biallelic event on short-read sequencing.”
What this piece can’t prove
  • The abstract does not describe why 14 nominated cases remained unresolved or quantify potential false negatives/positives.

3 further details could not be confirmed from the summary.

2secondary dataQuantify, at scale, how often multi-hit variant pairs in cancer genes exceed short-read phasing limits in a large clinical sequencing cohort, motivating the need for haplotype phasing in routine interpretation.Retrospective cohort computational analysisExpand

In plain English

Retrospective computational analysis of 4,496 MiOncoSeq clinical sequencing samples identified 17,519 multi-hit gene variant pairs; 78.7% of those pairs were separated by more than the ~500 bp short-read phasing limit, indicating most multi-hit pairs in this cohort cannot be phased by typical short-read approaches.

Key findings

  • In 4,496 MiOncoSeq samples the authors identified 17,519 multi-hit gene variant pairs; 78.7% of those pairs were separated by >500 bp, exceeding the short-read phasing limit.17,519 pairs; 78.7% >500 bp
“Analysis of 4,496 MiOncoSeq samples identified 17,519 multi-hit gene pairs, 78.7% of which exceeded the 500 bp short-read phasing limit”
What this piece can’t prove
  • Results are based on a single clinical sequencing dataset (MiOncoSeq) and may not generalize to other cohorts or sequencing methods.
  • Abstract does not provide detailed definitions or filters for multi-hit pairs, nor the exact methods used to compute distances.
  • The 500 bp phasing limit is an approximate boundary; method- and platform-specific variability could change the fraction of unphaseable pairs.
3secondary dataIdentify recurrent compound cis (same-allele) multi-variant oncogenic alleles in specific genes (e.g., NOTCH1, PIK3CA, PDGFRB, KIT) using long-read phasing to resolve co-occurring variants beyond short-read capability.Expand

In plain English

Using long-read haplotype phasing (nanopore), the study reports discovery of recurrent compound cis (same-allele) oncogenic alleles in NOTCH1, PIK3CA, PDGFRB, and KIT. In a separate prevalence analysis of 4,496 MiOncoSeq samples the authors identified 17,519 multi-hit gene pairs and found 78.7% exceeded a 500 bp short-read phasing limit, motivating use of long-read phasing to assign variants to cis and reveal recurrent same-allele compound variants beyond short-read capability.

Key findings

  • Long-read phasing revealed recurrent compound cis alleles in NOTCH1, PIK3CA, PDGFRB, and KIT.
  • Across 4,496 MiOncoSeq samples, 17,519 multi-hit gene pairs were identified; 78.7% exceeded the 500 bp short-read phasing limit.78.7% > 500 bp
“long-read phasing revealed recurrent compound cis alleles in NOTCH1, PIK3CA, PDGFRB, and KIT.”
What this piece can’t prove
  • Abstract provides limited methodological detail for the recurrence analysis (e.g., sample selection, counts per gene, statistical thresholds, and validation criteria are not reported).
  • Unclear how many samples underwent long-read sequencing specifically for the discovery of recurrent cis alleles versus how many were analyzed only in the short-read MiOncoSeq prevalence analysis.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 16 candidate papers

And 10 more candidates considered.